Cambrex upgrades to Swedish plant to include $3.5M for wastewater processing

Cambrex has announced new upgrades to its facility in Sweden.

New Jersey-based generic API maker Cambrex said it completed upgrades to increase manufacturing capacity at its facility in Karlskoga, Sweden, and will begin a $3.5 million multiyear project to improve the site’s wastewater processing capabilities.

It is part of a $9 million investment in the plant announced by Cambrex last year.

The latest expansion at the site to be completed includes new large-scale manufacturing capacity of various multipurpose reactors and a hydrogenation reactor. The construction of a new wastewater treatment plant is being phased in over a three-year period. Most of the construction is expected to be completed next year with additional upgrades to be finished in 2018 and 2019, the company said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“We are committed to investing in small molecule development and manufacturing capabilities, and ensuring our facilities are both flexible and efficient to respond to the evolving needs of our customers,” Bjarne Sandberg, managing director of the Karlskoga plant, said in a statement.

News of the upgrades to the Swedish plant follow the announcement by Cambrex of the construction of a $24 million, 4,500-square-foot highly potent API manufacturing facility at its facility in Charles City, Iowa, expected to open in 2019.

A year ago, the company shelled out about $25 million for clinical supply manufacturer Pharmacore and its 35,000-square-foot facility in High Point, North Carolina. That facility, which can produce batch sizes from milligrams to 100 kilos, is also licensed with the Drug Enforcement Administration to produce schedule II through schedule V controlled substances.